Following this week's European Commission approval of Roche/Genentech's Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global Insights' latest RealTime Dynamix(TM): Lupus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback